Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12123607 | 0.86 | SIGMAR1 (0.54) | ALDH1A1KMT2AHTR7POLBNOTUM | |
| SCHEMBL30641074 | 0.75 | CDK4 (0.67) | ALDH1A1MAPTLMNAHTTUSP2 | |
| SCHEMBL4320923 | 0.75 | CDK4 (0.67) | ALDH1A1MAPTLMNAHTTUSP2 | |
| SCHEMBL5070937 | 0.75 | NOTUM (0.58) | KMT2ALMNAMAPK1NOTUM | |
| SCHEMBL16897912 | 0.74 | ALDH1A1 (0.47) | ALDH1A1KMT2APOLBMAPK1NOTUM | |
| SCHEMBL30452423 | 0.73 | NOTUM (0.61) | KMT2ALMNAMAPK1NOTUM | |
| SCHEMBL3004386 | 0.73 | NOTUM (0.61) | KMT2ALMNAMAPK1NOTUM | |
| SCHEMBL10836168 | 0.73 | NOTUM (0.56) | KMT2ALMNAMAPK1NOTUM | |
| SCHEMBL12605565 | 0.71 | CDK4 (0.67) | ALDH1A1MAPTLMNAUSP2POLB | |
| SCHEMBL4334478 | 0.71 | CDK4 (0.67) | ALDH1A1MAPTLMNAUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2865381-A1 | ITK inhibitors for treating blood cell malignancies | Pharmacyclics, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | ALDH1A1 4370/4885MAPT 3284/4885KMT2A 1458/4885 |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | ALDH1A1 4370/4885MAPT 3284/4885KMT2A 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.